Why Is Cancer-Focused Chimerix Stock Trading Higher On Tuesday? [Yahoo! Finance]
Chimerix, Inc. (CMRX)
Last chimerix, inc. earnings: 2/25 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.chimerix.com/investor-relations
Company Research
Source: Yahoo! Finance
Application (NDA) seeking accelerated approval for dordaviprone for recurrent H3 K27M-mutant diffuse glioma in the U.S. before year-end A glioma is a tumor that originates in the glial cells of the brain or spinal cord and is the most common primary brain tumor. Chimerix stock is trading higher on a strong session volume of 4.31 million, compared to an average volume of 497.04K, as per data from Benzinga Pro The following recent program milestones and additional supportive data were extensively discussed with the FDA and will be included in the NDA: Substantial enrollment of the Phase 3 ACTION study. Phase 2 objective response rate of the 50-patient primary efficacy analysis as the primary basis of efficacy in the NDA. Several response assessments, under which dordaviprone demonstrated an objective response rate of 28%, a median duration of response of 10.4 months, and a median time to response of 4.6 months. Additional clinical data sets and patient narratives supportiv
Show less
Read more
Impact Snapshot
Event Time:
CMRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CMRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CMRX alerts
High impacting Chimerix, Inc. news events
Weekly update
A roundup of the hottest topics
CMRX
News
- Chimerix, Inc. (NASDAQ: CMRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.MarketBeat
- Chimerix, Inc. (NASDAQ: CMRX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $6.00 price target on the stock.MarketBeat
- Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End [Yahoo! Finance]Yahoo! Finance
- Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-EndGlobeNewswire
- Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
CMRX
Earnings
- 11/7/24 - Miss
CMRX
Sec Filings
- 12/10/24 - Form 8-K
- 11/14/24 - Form 8-K
- 11/7/24 - Form 10-Q
- CMRX's page on the SEC website